Correction: Progress in Clinical Gene Therapy for Cardiac Disorders (Molecular Diagnosis & Therapy, (2023), 27, 2, (179-191), 10.1007/s40291-022-00632-z)

Francisco J. Romeo, Spyros A. Mavropoulos, Kiyotake Ishikawa

Research output: Contribution to journalComment/debate

Abstract

In the original online published article, the Table 2 has several missing rows due to the error during typesetting. (Table presented.) Randomized clinical trials of gene therapy for therapeutic angiogenesis Trial name and publication year Therapeutic gene Vector Vector dose Route of delivery No. of patients Results KAT (2003) [25] VEGF-A165 Plasmid 2000 µg Intracoronary 103 Significant improvement in myocardial perfusion EUROINJECT-One (2005) [28] VEGF-A165 Plasmid 0.5 mg Intramyocardial 80 No changes on myocardial perfusion. Improved reginal wall motion. NORTHERN (2009) [29] VEGF-A165 Plasmid 2000 µg Intramyocardial 93 No changes on myocardial perfusion or exercise tolerance VIF-CAD (2011) [79] VEGF-A165+FGF-2 Plasmid 0.5 mg Intramyocardial 52 No changes on myocardial perfusion. Improvement in exercise tolerance and symptoms AGENT-3 and 4 (2007) [32] FGF-4 Adenovirus Two doses (1 × 109, 1 × 1010, vp) Intracoronary 532 Significant improvement in exercise tolerance, more in women NOVA (2011) [80] VEGF-A121 Adenovirus 4 × 1010 vp Intramyocardial 17 No significant change on myocardial perfusion or exercise tolerance Ad2HIF (2010) [81] HIF-1a Adenovirus Dose-escalation (1 × 109, 1 × 1010, 1 × 1011 vp) Intramyocardial 13 Safety trial, no adverse events REVASC (2006) [18] VEGF-A121 Adenovirus 4 × 1010 vp Intramyocardial 67 Significant improvement in exercise tolerance and symptoms. No effect on myocardial perfusion VEGF-2 (2002) [82] VEFG-C Plasmid Dose-escalation (200, 800, 2000 µg) Intramyocardial 19 Significant improvement for angina and exercise tolerance GENASIS (2011) [83] VEFG-C Plasmid N/A Intramyocardial 295 No significant effect on exercise tolerance KAT301 (2017) [27] VEGF-DdNdC Adenovirus Dose-escalation (1 × 109, 1 × 1010, 1 × 1011 vp) Intramyocardial 30 Iimprovement in myocardial perfusion ReGenHeart VEGF-DdNdC Adenovirus 1 × 1011 vp Intramyocardial 180 Phase II, ongoing RCT (NCT03039751) AFFIRM FGF-4 Adenovirus 6 × 109 vp Intracoronary 160 Phase III, ongoing RCT (NCT02928094) EXACT VEFG-A11 Adenovirus Dose-escalation (1 × 109, 1 × 1010, 4 × 1010, 1 × 1011 vp) Intramyocardial 41 Phase I/II, ongoing RCT (NCT04125732) FGF fibroblast growth factor, PET positron emission tomography, RCT randomized controlled trial, VEGF vascular endothelial growth factor, vp viral particles The correct version of Table 2 is as given below. The original article has been updated.

Original languageEnglish
Pages (from-to)551-552
Number of pages2
JournalMolecular Diagnosis and Therapy
Volume27
Issue number4
DOIs
StatePublished - Jul 2023

Fingerprint

Dive into the research topics of 'Correction: Progress in Clinical Gene Therapy for Cardiac Disorders (Molecular Diagnosis & Therapy, (2023), 27, 2, (179-191), 10.1007/s40291-022-00632-z)'. Together they form a unique fingerprint.

Cite this